FA
ACAD icon

FDx Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

FDx Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,963
Closed -$213K – 890
2015
Q4 		$213K Sell
5,963
-261
-4% -$9.2K 0.01% 810
2015
Q3 		$206K Buy
6,224
+636
+11% +$26.5K 0.02% 705
2015
Q2 		$234K Buy
+5,588
New +$216K 0.01% 840
2015
Q1 		– Sell
-7,253
Closed -$230K – 1863
2014
Q4 		$230K Buy
+7,253
New +$206K 0.01% 813

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

FDx Advisors's ACAD Position: Q1 2016 in Review

FDx Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2016, closing a stake of 5,963 shares — an estimated $213K sold.

FDx Advisors first reported a position in ACAD in Q4 2014 and held it in 4 quarters. The position peaked at $234K in Q2 2015. 213 funds tracked by Wall St. Rank hold ACAD as of Q1 2016.

  • FDx Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • FDx Advisors sold 5,963 Acadia Pharmaceuticals shares in Q1 2016, an estimated $213K.
  • FDx Advisors first reported a position in Acadia Pharmaceuticals in Q4 2014 and held it in 4 quarters.
  • FDx Advisors's Acadia Pharmaceuticals position peaked at $234K in Q2 2015.
  • 213 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2016.

Based on FDx Advisors's 13F filing for Q1 2016, filed 17 May 2016.